NASH
54 programs · 52 companies
Programs
54
Companies
52
Trials
47
MOAs
37
BiTEVEGFiHER2PI3KiIL-17iSOS1iGLP-1agCFTRmodAnti-TauHPK1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Phase 2 | MDM2 | ||
| MRK-5413 | Phase 1 | GLP-1R | ||
| SNY-7254 | Phase 2 | CFTR | ||
| Capifutibatinib | Approved | PRMT5 | ||
| Fixainavolisib | Preclinical | CDK2 | ||
| DSN-6862 | Preclinical | IL-23 | ||
| MRN-7601 | Phase 2 | IL-13 | ||
| Ivotuximab | Phase 2 | CD123 | ||
| Rilucapivasertib | Phase 2/3 | JAK2 | ||
| 452-5607 | Preclinical | PD-1 | ||
| IPN-4133 | NDA/BLA | PI3Kα | ||
| Doxafutibatinib | Phase 1 | BET | ||
| Gozecagene | Phase 1 | GPRC5D | ||
| Zenozumab | Phase 3 | PI3Kα | ||
| PEK-IIT-810 | Phase 1/2 | BCMA | ||
| JOH-IIT-536 | Phase 2 | C5 | ||
| IMM-7074 | Phase 1/2 | WRN | ||
| MGX-719 | Preclinical | IL-23 | ||
| Tixaglumide | Preclinical | C5 | ||
| Taladerotide | Phase 2/3 | CFTR | ||
| SYR-7044 | Phase 3 | PARP | ||
| Miricapivasertib | NDA/BLA | DLL3 | ||
| Terafotisoran | Phase 1 | IL-13 | ||
| KAL-3824 | Phase 1/2 | FLT3 | ||
| Tixazanubrutinib | Phase 1 | FGFR | ||
| Datoderotide | Phase 3 | LAG-3 | ||
| Ribozasiran | Phase 2/3 | B7-H3 | ||
| Adagrazasiran | Approved | CD3 | ||
| MRN-8142 | Phase 2/3 | PI3Kα | ||
| Pexaglumide | Phase 1/2 | DLL3 | ||
| Tixazasiran | Phase 1 | MET | ||
| Tezetapinarof | Phase 1 | JAK1 | ||
| Nidavorutinib | Phase 2 | SMN2 | ||
| AMB-378 | Phase 2 | BCMA | ||
| NTR-7891 | Phase 1/2 | CD3 | ||
| Polafutibatinib | Preclinical | PLK4 | ||
| INT-9034 | Phase 1/2 | Menin | ||
| CCC-2073 | Phase 1/2 | AuroraA | ||
| BIO-8650 | Phase 2 | CGRP | ||
| Daracilimab | Phase 2 | CD38 | ||
| Rimanaritide | Phase 2/3 | CDK4/6 | ||
| Polavorutinib | Phase 3 | HER2 | ||
| MAG-6737 | Preclinical | B7-H3 | ||
| VVY-8289 | Phase 2/3 | PCSK9 | ||
| GRA-2645 | Phase 2 | FLT3 | ||
| AII-IIT-540 | Phase 1/2 | KRASG12D | ||
| SIR-IIT-294 | Approved | B7-H3 | ||
| Polalemzoparlimab | Phase 1 | WEE1 | ||
| Voxatenlimab | Approved | PI3Kα | ||
| ANG-3408 | Phase 2/3 | BCL-2 | ||
| BLC-6641 | Phase 3 | AuroraA | ||
| Nidatenlimab | Phase 1 | AuroraA | ||
| VEE-8520 | NDA/BLA | ALK | ||
| 115-7101 | Phase 1 | SGLT2 |
Trials (47)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08494268 | MRK-5413 | Phase 1 | Not yet recr... |
| NCT08360418 | MRK-5413 | Phase 1 | Completed |
| NCT05406044 | DSN-6862 | Preclinical | Terminated |
| NCT03635868 | MRN-7601 | Phase 2 | Terminated |
| NCT06192622 | MRN-7601 | Phase 2 | Not yet recr... |
| NCT07642259 | Ivotuximab | Phase 2 | Active |
| NCT04195036 | Rilucapivasertib | Phase 2/3 | Terminated |
| NCT06557042 | 452-5607 | Preclinical | Completed |
| NCT03486024 | Doxafutibatinib | Phase 1 | Completed |
| NCT04586726 | Gozecagene | Phase 1 | Completed |
| NCT06626858 | Zenozumab | Phase 3 | Not yet recr... |
| NCT05940889 | PEK-IIT-810 | Phase 1/2 | Completed |
| NCT05817394 | JOH-IIT-536 | Phase 2 | Completed |
| NCT06631872 | MGX-719 | Preclinical | Terminated |
| NCT04102544 | Taladerotide | Phase 2/3 | Recruiting |
| NCT03760486 | SYR-7044 | Phase 3 | Terminated |
| NCT06315848 | SYR-7044 | Phase 3 | Terminated |
| NCT06952577 | Miricapivasertib | NDA/BLA | Recruiting |
| NCT08871647 | Terafotisoran | Phase 1 | Not yet recr... |
| NCT06168115 | Terafotisoran | Phase 1 | Terminated |